Top Page
Cann Group
(Sydney:CAN)
Cann Group (CAN) vs. iShares MSCI Australia ETF (EWA)
Cann Group Business Overview & Revenue Model
Cann Group Financial Statement Overview
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 15.37M | 13.78M | 6.41M | 4.29M | 647.22K |
| Gross Profit | 3.19M | 20.63M | 11.24M | 4.25M | 6.22K |
| EBITDA | -35.54M | -17.76M | -19.79M | -17.29M | -13.91M |
| Net Income | -51.24M | -33.79M | -26.47M | -25.10M | -16.94M |
Balance Sheet | |||||
| Total Assets | 92.77M | 129.47M | 139.66M | 101.79M | 76.40M |
| Cash, Cash Equivalents and Short-Term Investments | 1.64M | 765.00K | 1.91M | 3.10M | 1.55M |
| Total Debt | 72.47M | 60.97M | 47.16M | 680.00K | 9.32M |
| Total Liabilities | 78.85M | 70.20M | 54.76M | 9.92M | 15.33M |
| Stockholders Equity | 13.92M | 59.26M | 84.90M | 91.87M | 61.07M |
Cash Flow | |||||
| Free Cash Flow | -17.69M | -25.94M | -65.60M | -37.10M | -51.98M |
| Operating Cash Flow | -15.19M | -22.84M | -20.43M | -20.83M | -17.62M |
| Investing Cash Flow | 1.18M | -28.00K | -45.16M | -17.08M | -34.36M |
| Financing Cash Flow | 14.77M | 21.71M | 64.41M | 39.47M | 7.15M |
Cann Group Technical Analysis
Cann Group Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | AU$42.38M | 19.12 | 4.85% | ― | 5.76% | -79.76% | |
53 Neutral | AU$23.85M | ― | -218.38% | ― | -14.30% | 29.69% | |
50 Neutral | AU$2.51B | 3.43 | -57.47% | 2.67% | 36.73% | 13.67% | |
46 Neutral | $10.42M | ― | -164.01% | ― | -18.80% | -46.65% | |
39 Underperform | AU$4.26M | ― | ― | ― | ― |
Cann Group Corporate Events
Cann Group Limited has announced the quotation of 15,130,872 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of July 8, 2025. This move is part of the company’s strategic efforts to enhance its market presence and provide liquidity to its stakeholders, potentially strengthening its position in the medicinal cannabis sector.
Cann Group Limited has announced the conversion of Ms. Jenni Pilcher’s role as CEO & Managing Director from a fixed-term contract to a permanent position. This decision reflects the board’s satisfaction with her performance and aligns with the company’s best interests, ensuring stability in its leadership as it continues to focus on its strategic objectives.
Cann Group Limited has received a second advance of $315,552 from Radium Capital, providing early access to its expected R&D Tax Incentive for FY2025. This funding, along with a previous advance, totals $1,152,021 and will be repaid upon receipt of the R&D rebate or by 31 October 2025. This financial maneuver supports Cann Group’s ongoing R&D activities, potentially strengthening its position in the cannabis industry by ensuring continuous innovation and product development.
Cann Group Limited has announced the quotation of 13,970,244 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of June 13, 2025. This move reflects the company’s efforts to enhance its capital structure and potentially expand its market presence, which could have significant implications for its stakeholders and position within the medicinal cannabis industry.
Cann Group Limited announced the cessation of several securities due to the lapse of conditional rights, as the conditions for these securities were not met or became incapable of being satisfied. This cessation involves a total of 3,795,886 securities, impacting the company’s issued capital and potentially affecting stakeholder interests.
Cann Group Limited announced the issuance of 49,376,573 unquoted options, set to expire on June 4, 2027, with an exercise price of $0.03. This issuance is part of a previously announced transaction, indicating strategic financial maneuvers to support the company’s growth and operational objectives. The move could potentially impact the company’s market positioning by enhancing its financial flexibility and offering stakeholders an opportunity for future engagement.
Cann Group Limited has resolved its legal dispute with Rua Biosciences Limited by entering into a confidential deed of settlement and release, which includes mutual release from claims and two commercial agreements for Cann to supply medicinal cannabis products to Rua for distribution in Australia and New Zealand. This settlement not only resolves the dispute but also establishes a new commercial relationship between the two companies, potentially impacting their operations and market positioning positively.
Cann Group Limited has announced the issuance of 7,924,832 unquoted equity securities in the form of options set to expire on June 2, 2027, with an exercise price of $0.0508. This move is part of previously announced transactions and is not intended for quotation on the ASX, potentially impacting the company’s financial strategy and stakeholder interests by expanding its equity base.
Cann Group Limited has announced the issuance of 1,746,147 unquoted equity securities in the form of options set to expire on June 2, 2027, with an exercise price of $0.0573. This issuance is part of a previously announced transaction and is not intended to be quoted on the ASX, potentially impacting the company’s financial strategy and stakeholder interests by expanding its equity base.
Cann Group Limited announced the results of its General Meeting, where all resolutions were passed following a poll vote. The meeting included significant decisions such as the election of a director and the ratification of share and option issuances, which are expected to impact the company’s strategic direction and stakeholder interests positively.
Cann Group Limited announced a presentation by CEO Jenni Pilcher at their Extraordinary General Meeting, focusing on the company’s operations, sales, funding, and strategy. This announcement highlights the company’s ongoing efforts to strengthen its market position and operational capabilities, potentially impacting its stakeholders positively.
Cann Group Limited has announced the application for quotation of 11,607,322 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of May 20, 2025. This move is part of the company’s strategic efforts to bolster its financial position and enhance its market presence, potentially impacting its operations and offering new opportunities for stakeholders.
Cann Group Limited announced the quotation of 7,676,567 fully paid ordinary securities on the Australian Securities Exchange (ASX), effective April 30, 2025. This move is expected to enhance the company’s capital structure and provide additional liquidity, potentially strengthening its market position and offering more opportunities for stakeholders.
Cann Group Limited has announced an Extraordinary General Meeting (EGM) scheduled for May 30, 2025, to seek shareholder approval for several resolutions related to recent financing transactions. These include ratifications and approvals for the issuance of shares and options as part of private placements and convertible notes, aimed at securing funding to optimize production and support strategic growth. The board supports these resolutions, which are expected to provide the company with the flexibility to pursue future expansion and growth opportunities.
Cann Group Limited announced the outcomes of a pilot clinical trial investigating medicinal cannabis as a treatment for Tourette syndrome in adolescents. Conducted by the Murdoch Children’s Research Institute and the Royal Children’s Hospital, the trial showed preliminary evidence supporting the efficacy and safety of medicinal cannabis, with high levels of acceptability reported by parents. The study suggests the feasibility of using medicinal cannabis for Tourette syndrome, recommending further research with a larger cohort to confirm these findings.
Cann Group Limited has secured an $836,469 funding advance from Radium Capital, which provides early access to its expected R&D Tax Incentive for FY2025. This advance will support the company’s strategy of supplying the medicinal cannabis market with unique products, including those sold under its Botanitech brand in collaboration with Chemist Warehouse outlets. The advance, under a loan agreement with a 15% annual interest rate, will be repaid upon receipt of the R&D Refund or by 31 October 2025. This move is expected to bolster Cann Group’s operations and strengthen its market positioning in the medicinal cannabis industry.